financetom
Technology
financetom
/
Technology
/
SimBioSys and Ricoh 3D for Healthcare to Spotlight AI-Powered 3D Visualization in Webinar Featuring Clinical Use of TumorSight™ Viz
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SimBioSys and Ricoh 3D for Healthcare to Spotlight AI-Powered 3D Visualization in Webinar Featuring Clinical Use of TumorSight™ Viz
Mar 10, 2026 9:14 PM

Vincent Reid, MD, FACS, Chairman of Surgery and Medical Director at the Hall Perrine Cancer Center, Mercy Cedar Rapids, to share clinical experience and real-world case studies using TumorSight™ Viz

CHICAGO and EXTON, Pa., Dec. 2, 2025 /PRNewswire/ -- SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, and Ricoh 3D for Healthcare, LLC, a wholly owned subsidiary of Ricoh USA, Inc. focused on delivering FDA-cleared, patient-specific medical devices through centralized and point-of-care manufacturing, today announced an upcoming educational webinar highlighting real-world clinical use of TumorSight™ Viz, the FDA-cleared 3D surgical visualization platform transforming how surgeons evaluate breast-conserving options and engage patients in their care. The live virtual event, "AI-Powered 3D Visualization for Smarter Breast Surgery," will be held on Wednesday, December 10, 2025 at 7:00 p.m. ET / 4:00 p.m. PT. Attendees may register here, or by visiting Ricoh 3D for Healthcare in Booth #4047 at the Radiological Society of North America (RSNA) Annual Meeting in Chicago this week.

The webinar will feature Vincent Reid, MD, FACS, Chairman of Surgery and Medical Director of the Hall Perrine Cancer Center at Mercy Cedar Rapids, who will share his experience incorporating TumorSight Viz into surgical planning, including case examples recently featured by ABC News Digital and Good Morning America. Dr. Reid will be joined by Lexi Gormley, PhD, Senior Clinical Applications Specialist at Ricoh 3D for Healthcare, with moderation by Barry Rosen, MD, FACS, Chief Medical Officer of SimBioSys.

"With tens of thousands of women undergoing breast-conserving surgery each year in the United States, surgeons are seeking new tools that bring greater clarity, confidence, and personalization to the planning process," said Stacey Stevens, President and CEO of SimBioSys. "TumorSight Viz provides surgeons with an entirely new way to understand tumor size, shape, and spatial relationships within the breast—insight that is difficult to achieve with traditional imaging alone. We are pleased to partner with Ricoh to bring this educational opportunity to clinicians nationwide and to highlight how advanced, AI-powered 3D visualization can support more precise and informed surgical decisions."

TumorSight Viz converts standard breast MRI into intuitive, patient-specific 3D models that reveal tumor size, location, and proximity to surrounding tissues. The technology provides surgeons with a level of anatomical context that supports a deeper understanding of what is surgically feasible and enhances communication with patients about their treatment options. The platform, which recently received its third FDA clearance, has been validated across more than 1,600 retrospective cases from more than nine institutions.1,2

"TumorSight Viz brings a new degree of clarity to breast-conserving and oncoplastic surgical planning," said Vincent Reid, MD, FACS, Mercy Cedar Rapids. "Having a precise, intuitive view of the tumor and its relationship to the surrounding breast anatomy allows us to assess feasibility more clearly and consistently. It enhances the planning process and supports more meaningful discussions with patients about their options."

"At Ricoh, we are committed to equipping clinicians with technologies that strengthen surgical precision and elevate the standard of care," said Lexi Gormley, PhD, Senior Clinical Applications Specialist, Ricoh 3D for Healthcare. "This webinar offers breast surgeons a firsthand look at how TumorSight Viz fits into everyday practice—how it informs decision-making, supports oncoplastic planning, and enhances the overall patient experience. We're excited to partner with SimBioSys to bring these insights directly to the clinical community."

The upcoming webinar builds on the companies' recently announced strategic alliance aimed at expanding market access to TumorSight Viz nationwide. The program also follows strong momentum for SimBioSys, including national recognition of its technology by ABC News Digital and Good Morning America, where real-world use at Mercy Cedar Rapids was highlighted as part of Breast Cancer Awareness Month programming.

About SimBioSys

SimBioSys is an AI-driven precision medicine company revolutionizing how cancer is understood and treated. By converting standard medical imaging into AI-powered, decision-driving intelligence, SimBioSys empowers clinicians with clear, contextual, and actionable insights to individualize care. Its FDA-cleared TumorSight™ Viz platform and in-development TumorSight™ Risk solution combine AI and spatial biophysics to deliver greater confidence, precision, and personalization in cancer treatment. For more information, visit www.simbiosys.com.

About RICOH 3D for Healthcare

Ricoh 3D for Healthcare, LLC is a wholly owned subsidiary of Ricoh USA, Inc., focused on delivering FDA-cleared, patient-specific medical devices through centralized and point-of-care manufacturing. The company supports hospitals and health systems with clinical-grade anatomic models, surgical planning tools, and scalable production partnerships. In addition to hospital-based services, Ricoh 3D for Healthcare collaborates with MedTech innovators to manufacture and distribute next-generation personalized devices across the United States. For more information, please visit ricoh-usa.com/3d-for-healthcare. 

Contact

SimBioSys, Inc.

[email protected]

Ricoh USA, Inc.

[email protected] 

Porter Novelli for Ricoh USA, Inc.

[email protected] 

References:

Weitz M, Pfeiffer JR, Patel S, Biancalana M, et al. (2024). Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients. npj Breast Cancer. https://doi.org/10.1038/s41523-024-00696-6Pekis A, Kannan V, Kaklamanos E, Antony A, Patel S, Earnest T. (2024). Seeing beyond cancer: Multi-institutional validation of object localization and 3D semantic segmentation using deep learning for breast MRI. In: Medical Imaging 2024: Image Processing (Vol. 12927, 129270H). SPIE. https://doi.org/10.1117/12.3009341

View original content to download multimedia:https://www.prnewswire.com/news-releases/simbiosys-and-ricoh-3d-for-healthcare-to-spotlight-ai-powered-3d-visualization-in-webinar-featuring-clinical-use-of-tumorsight-viz-302629681.html

SOURCE SimBioSys

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
G2 Unveils Innovations to Help Software Companies Build Brand Visibility in the AI Search Era
G2 Unveils Innovations to Help Software Companies Build Brand Visibility in the AI Search Era
Sep 16, 2025
Go-to-market teams can track LLM citations, control their brand narrative, influence buyers earlier, and prove ROI with new G2 solutions. CHICAGO--(BUSINESS WIRE)-- G2, the world’s largest and most trusted software marketplace, today announced new product offerings to help software companies adapt to the new buying journey, amplify their brand influence on in-market buyers, and show a tangible return on...
Digital Brands Group Outlines Strategy to Deliver Robust Suite of Technology Tools Powered by AI and Quantum-Resilient Security for eCommerce
Digital Brands Group Outlines Strategy to Deliver Robust Suite of Technology Tools Powered by AI and Quantum-Resilient Security for eCommerce
Sep 16, 2025
Austin, Texas, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Digital Brands Group, Inc. ( DBGI )  (the “Company” or “DBG”) today announced its strategic direction to deliver a robust suite of technology tools for the eCommerce sector, powered by artificial intelligence (AI) and quantum resilient security. The suite is designed to address critical needs such as automated IP protection, advanced data...
Fabric Networks purchases commercial license from Arqit to deploy quantum‑safe networks at scale
Fabric Networks purchases commercial license from Arqit to deploy quantum‑safe networks at scale
Sep 16, 2025
LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. ( ARQQ ) (“Arqit”), a global leader in quantum‑safe encryption, today announced that Fabric Networks has purchased a full commercial Private Instance (PI) license for Arqit’s NetworkSecure™ platform. This agreement will enable Fabric Networks to scale quantum-safe network deployment across its customers’ infrastructure. Key highlights: Fabric Networks infrastructure includes fibre‑optic...
Zip Becomes First Procurement Platform Named Finalist in Fast Company’s Innovation by Design Awards
Zip Becomes First Procurement Platform Named Finalist in Fast Company’s Innovation by Design Awards
Sep 16, 2025
Five-year-old AI platform recognized in the world’s most prestigious design competition for bringing consumer-grade design excellence to traditionally overlooked business processes SAN FRANCISCO--(BUSINESS WIRE)-- Zip, the world’s leading agentic procurement orchestration platform, today announced its selection as a finalist in Fast Company’s 2025 Innovation by Design Awards, marking the first time a procurement platform has earned this recognition in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved